Replication Data for: Conjugation strategy shapes antitumor efficacy and enables dose-sparing in non-antibody protein nanoconjugates

Dataset

DOI

S'inclouen les dades brutes de cadascuna de les figures que composen l'article cientific publicat al Materials Today Bio. Totes les dades de DLS s'han estret del programa ZS Explorer. Totes les dades de fluorescencia ex-vivo dels teixits i luminiscencia in-vivo dels animals s'han obtingut a partir del IVIS Spectrum 200. Totes les dades de citrometria de flux s'han obtingut amb el MACSQuant 10. Totes les dades viabilitat celullar s'han obtingut amb el lector de plaques FLUOStar Optima.

The authors are indebted to Instituto de Salud Carlos III (PI20/00400 and PI23/00318 to UU, PI21/00150 and PI24/01476 to RM, PI24/ 00012 to IC) cofounded by European Regional Development Fund (ERDF, a way to make Europe); to Agencia Estatal de Investigación (PDC2022-133858-I00 to EV and AV, and CNS2024-154280 to UU) to CIBER-BBN (NANOLINK and AMATOX to UU, 4NanoMets to RM, VENOM4CANCER to AV, NANOREMOTE to EV), to Fundació Investigació Salut i Progress (Miquel Rutllant 2024 grant to UU) and to AGAUR (2021 SGR-01140 to RM, 2021 SGR-00092 to AV). This work was also supported by CIBER-Consorcio Centro de Investigación Biomédica en Red- (CB06/01/1031, CB06/01/0014, CB06/01/0019 and CB06/07/0011), and by CERCA programme (Generalitat de Catalunya). UU and LA-C were supported by Miguel Servet contract (CP19/00028 and CP24/00111 respectively) and AR was supported by a PFIS predoctoral fellowship (FI21/00012), all from ISCIII co-funded by European Social Fund (ESF, investing in your future). LAA was supported by La Caixa INPhINIT Fellowship (LCF/BQ/DI24/12070029). Protein production and biodistribution studies were partially performed by the ICTS ‘‘NANBIOSIS”, more specifically by the Protein Production Platform (CIBER in Bioengineering, Biomaterials and Nanomedicine/IBB, at the UAB http://www.nanbiosis.es/portfolio/u1-protein-production-platfo rm-ppp/) and by the Nanotoxicology U18 unit (http://www.nanbiosis. es/portfolio/u18-nanotoxicology-unit/) of the CIBER in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN) at the Sant Pau Research Institute (entry accesses 3161, 3915 and 4150)). Molecular graphics were performed with UCSF Chimera and ChimeraX, developed by the Resource for Biocomputing, Visualization, and Informatics at the University of California, San Francisco, with support from the National Institutes of Health R01-GM129325 and the Office of Cyber Infrastructure and Computational Biology, National Institute of Allergy and Infectious Diseases.

Identifier
DOI	https://doi.org/10.34810/data2902
Related Identifier	IsSupplementTo https://doi.org/10.1016/j.mtbio.2025.102698
Metadata Access	https://dataverse.csuc.cat/oai?verb=GetRecord&metadataPrefix=oai_datacite&identifier=doi:10.34810/data2902

Provenance
Creator	Unzueta, Ugutz ; CASANOVA RIGAT, ISOLDA ; Rueda, Ariana ; Garcia-León, Annabel ; Arena, Lourdes Ailen ; Mendoza, Julian Ignacio ; Aviñó, Ana (ORCID: 0000-0003-3047-738X); Fabrega, Carme ; eritja, ramon ; Paez, David ; Alba-Castellon, Lorena ; Vazquez, Esther ; Villaverde, Antonio ; Mangues, Ramon
Publisher	CORA.Repositori de Dades de Recerca
Contributor	Unzueta, Ugutz; Institut de Recerca Sant Pau; Rueda, Ariana. a Institut de Recerca Sant Pau (IR SANT PAU), b CIBER de Bioingeniería, Biomateriales y Nanomedicina, Instituto de Salud Carlos III, c Josep Carreras Leukaemia Research Institute; Garcia-Leon, Annabel. a Institut de Recerca Sant Pau (IR SANT PAU), b CIBER de Bioingeniería, Biomateriales y Nanomedicina, Instituto de Salud Carlos III, c Josep Carreras Leukaemia Research Institute; Arena, Lourdes A. a Institut de Recerca Sant Pau (IR SANT PAU), c Josep Carreras Leukaemia Research Institute; Mendoza, Julian I. a Institut de Recerca Sant Pau (IR SANT PAU), b CIBER de Bioingeniería, Biomateriales y Nanomedicina, Instituto de Salud Carlos III, c Josep Carreras Leukaemia Research Institute; Aviñó, Anna. b CIBER de Bioingeniería, Biomateriales y Nanomedicina, Instituto de Salud Carlos III, f Institute for Advanced Chemistry of Catalonia (IQAC), CSIC; Fabrega, Carme. b CIBER de Bioingeniería, Biomateriales y Nanomedicina, Instituto de Salud Carlos III, f Institute for Advanced Chemistry of Catalonia (IQAC), CSIC; Eritja, Ramon. b CIBER de Bioingeniería, Biomateriales y Nanomedicina, Instituto de Salud Carlos III, f Institute for Advanced Chemistry of Catalonia (IQAC), CSIC; Paez, David. a Institut de Recerca Sant Pau (IR SANT PAU), g Department of Medical Oncology, Hospital de la Santa Creu I Sant Pau, h CIBER de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III; Alba-Castellon, Lorena. a Institut de Recerca Sant Pau (IR SANT PAU), Sant Quintí 77-79, 08041 Barcelona, Spain b CIBER de Bioingeniería, Biomateriales y Nanomedicina, Instituto de Salud Carlos III, Spain c Josep Carreras Leukaemia Research Institute, Barcelona, Spain; Vazquez, Esther. b CIBER de Bioingeniería, Biomateriales y Nanomedicina, Instituto de Salud Carlos III, d Institut de Biotecnologia i de Biomedicina, Universitat Autònoma de Barcelona, e Departament de Genètica i de Microbiologia, Universitat Autònoma de Barcelona; Villaverde, Antonio. b CIBER de Bioingeniería, Biomateriales y Nanomedicina, Instituto de Salud Carlos III, d Institut de Biotecnologia i de Biomedicina, Universitat Autònoma de Barcelona, e Departament de Genètica i de Microbiologia, Universitat Autònoma de Barcelona; Mangues, Ramon. a Institut de Recerca Sant Pau (IR SANT PAU), b CIBER de Bioingeniería, Biomateriales y Nanomedicina, Instituto de Salud Carlos III, c Josep Carreras Leukaemia Research Institute; Casanova, Isolda. a Institut de Recerca Sant Pau (IR SANT PAU), b CIBER de Bioingeniería, Biomateriales y Nanomedicina, Instituto de Salud Carlos III, c Josep Carreras Leukaemia Research Institute; Unzueta, Ugutz. a Institut de Recerca Sant Pau (IR SANT PAU), b CIBER de Bioingeniería, Biomateriales y Nanomedicina, Instituto de Salud Carlos III, c Josep Carreras Leukaemia Research Institute, e Departament de Genètica i de Microbiologia, Universitat Autònoma de Barcelona
Publication Year	2026
Funding Reference	https://ror.org/00ca2c886 CP19/00028; CP24/00111 ; https://ror.org/00ca2c886 PI20/00400; PI23/00318; PI21/00150; PI24/01476; PI24/ 00012 ; https://ror.org/00ca2c886 FI21/00012 ; https://ror.org/003x0zc53 PDC2022-133858-I00; CNS2024-154280 ; https://ror.org/01bg62x04 2021 SGR-01140; 2021 SGR-00092
Rights	CC BY-NC 4.0; info:eu-repo/semantics/openAccess; http://creativecommons.org/licenses/by-nc/4.0
OpenAccess	true
Contact	Unzueta, Ugutz (Institut de Recerca Sant Pau)

Representation
Resource Type	Experimental data; Dataset
Format	text/tab-separated-values; text/plain
Size	1176; 182; 614; 609; 40; 77; 2512; 235; 815; 1306; 237; 1220; 302; 37141; 275; 55; 233; 240; 13381
Version	1.0
Discipline	Life Sciences; Medicine